The Interleukin 33 pipeline drugs market research report outlays comprehensive information on the Interleukin 33 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 33 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Respiratory, Immunology, Dermatology, and Women’s Health which include the indications Chronic Obstructive Pulmonary Disease (COPD), Asthma, Autoimmune Disorders, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Atopic Dermatitis (Atopic Eczema), and Endometriosis. It also reviews key players involved in Interleukin 33 targeted therapeutics development with respective active and dormant or discontinued products.
The Interleukin 33 pipeline targets constitutes close to 16 molecules. Out of which, approximately 16 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 2, 3, 2, 2, and 4 respectively.
Interleukin 33 overview
Interleukin 33 (IL33) is a cytokine that binds to and signals through the IL1RL1/ST2 receptor, which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. It is involved in the maturation of Th2 cells, inducing the secretion of T-helper type 2-associated cytokines.
For a complete picture of Interleukin 33’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
